{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:10:33Z","timestamp":1721887833371},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10147-024-02572-6","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:01:51Z","timestamp":1718971311000},"page":"1081-1087","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology"],"prefix":"10.1007","volume":"29","author":[{"given":"Takeshi","family":"Hirose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"1","key":"2572_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jos.2016.10.006","volume":"22","author":"K Ogura","year":"2017","unstructured":"Ogura K, Higashi T, Kawai A (2017) Statistics of bone sarcoma in Japan: report from the bone and soft tissue tumor registry in Japan. J Orthop Sci 22(1):133\u2013143","journal-title":"J Orthop Sci"},{"issue":"5","key":"2572_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2106\/00004623-200005000-00007","volume":"82","author":"B Widhe","year":"2000","unstructured":"Widhe B, Widhe T (2000) Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 82(5):667\u2013674","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"2572_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cancergen.2011.07.008","volume":"204","author":"S Sankar","year":"2011","unstructured":"Sankar S, Lessnick SL (2011) Promiscuous partnerships in Ewing\u2019s sarcoma. Cancer Genet 204(7):351\u2013365","journal-title":"Cancer Genet"},{"issue":"1","key":"2572_CR4","first-page":"111","volume":"11","author":"G Bacci","year":"2004","unstructured":"Bacci G, Ferrari S, Longhi A et al (2004) Role of surgery in local treatment of Ewing\u2019s sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep 11(1):111\u2013120","journal-title":"Oncol Rep"},{"issue":"2","key":"2572_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijrobp.2007.06.032","volume":"70","author":"DJ Indelicato","year":"2008","unstructured":"Indelicato DJ, Keole SR, Shahlaee AH et al (2008) Long-term clinical and functional outcomes after treatment for localized Ewing\u2019s tumor of the lower extremity. Int J Radiat Oncol Biol Phys 70(2):501\u2013509","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2572_CR6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier HE, Krailo MD, Tarbell NJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348(8):694\u2013701","journal-title":"N Engl J Med"},{"issue":"33","key":"2572_CR7","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","volume":"30","author":"RB Womer","year":"2012","unstructured":"Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol 30(33):4148\u20134154","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"2572_CR8","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F et al (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248-251","journal-title":"Ann Oncol"},{"key":"2572_CR9","unstructured":"NCCN (2022) NCCN Clinical Practice Guidelines in Oncology Hematopoietic Growth Factors Version 1.2022"},{"issue":"28","key":"2572_CR10","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"2572_CR11","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248-251","journal-title":"Ann Oncol"},{"key":"2572_CR12","unstructured":"(Guidelines\u00ae) NCPGN (2022) Hematopoietic Growth Factors Version 1.2022"},{"key":"2572_CR13","volume-title":"Medical information network distribution service (Minds) handbook for clinical practice guideline development 2014 (in Japanese)","author":"T Morizane","year":"2014","unstructured":"Morizane T, Yoshida M, Kojimahara N (2014) Medical information network distribution service (Minds) handbook for clinical practice guideline development 2014 (in Japanese). Igaku Shoin, Tokyo"},{"key":"2572_CR14","unstructured":"Minds Manual Developing Committee (2017) Minds manual for clinical practice guideline development 2017 (in Japanese). Japan Council for Quality Health Care, Tokyo"},{"key":"2572_CR15","unstructured":"Kojimahara NNT, Morizane T (2017) Minds Manual for Guideline Development 2017. Japan Council for Quality Health Care"},{"issue":"7650","key":"2572_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"1","key":"2572_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/pbc.20820","volume":"47","author":"C Juergens","year":"2006","unstructured":"Juergens C, Weston C, Lewis I et al (2006) Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47(1):22\u201329","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2572_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.1999.17.1.180","volume":"17","author":"NM Marina","year":"1999","unstructured":"Marina NM, Pappo AS, Parham DM et al (1999) Chemotherapy dose-intensification for pediatric patients with Ewing\u2019s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children\u2019s Research Hospital. J Clin Oncol 17(1):180\u2013190","journal-title":"J Clin Oncol"},{"issue":"5","key":"2572_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28194","volume":"67","author":"M Chin","year":"2020","unstructured":"Chin M, Yokoyama R, Sumi M et al (2020) Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: results of the Japan Ewing Sarcoma Study 04. Pediatr Blood Cancer 67(5):e28194","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2572_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<901::AID-CNCR30>3.0.CO;2-X","volume":"78","author":"LH Wexler","year":"1996","unstructured":"Wexler LH, DeLaney TF, Tsokos M et al (1996) Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing\u2019s sarcoma family of tumors. Cancer 78(4):901\u2013911","journal-title":"Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02572-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:31:31Z","timestamp":1721885491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02572-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02572-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kenji Tsuchihashi received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Novartis Pharma. Yukinori Ozaki received honoraria from Daiichi-Sankyo, Pfizer, Chugai, Lilly, and Kyowa Kirin. Eiki Ichihara received honoraria from Eli Lilly and research funding from MSD, Ono Pharmaceutical, Jansen Pharma, and Takeda Pharmaceutical. Yuji Miura received honoraria from Ono Pharmaceutical, MSD, Takeda Pharmaceuticals, Eisai, Bristol Myers Squibb, and research funding from Ono Pharmaceutical and MSD. Shingo Yano received research funding from Otsuka Pharmaceutical. Dai Maruyama received honoraria from Ono Pharmaceutical, Janssen Pharma, Nippon Shinyaku, Eisai, Mundipharma, Kyowa Kirin, Chugai Pharmaceutical, Zenyaku, MSD, SymBio, Sanofi, AbbVie, Takeda Pharmaceutical, AstraZeneca, Bristol Myers Squibb, and Genmab, and research funding from Amgen, Astellas Biopharma, Novartis, Kyowa Kirin, Ono Pharmaceutical, Chugai Pharmaceutical, Janssen Pharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Astellas, Bristol Myers Squibb, AbbVie, Eisai, MSD, Taiho Pharmaceutical, AstraZeneca, Eli Lilly, and Genmab. Tetsuhiro Yoshinami received honoraria from Kyowa Kirin, Pfizer, Chugai Pharmaceutical, Eli Lilly, MSD, AstraZeneca, and Eizai. Takashi Motohashi received honoraria from AstraZeneca, Chugai Pharmaceutical, and Myriad Genetics. Eishi Baba received honoraria from Chugai Pharmaceutical and Daiichi-Sankyo, and research funding from Taiho Pharmaceutical and Chugai Pharmaceutical. Toshio Kubo received honoraria from Chugai Pharmaceutical. Takahiro Kimura received honoraria from Sanofi. Shinji Nakao received honoraria from Kyowa Kirin. Atsushi Sato received honoraria from Chugai Pharmaceutical, and Taiho Pharmaceutical, and research funding from Chugai Pharmaceutical, and Taiho Pharmaceutical. Toshimi Takano received honoraria from Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly. The other authors certify that no conflicts of interest exist in relation to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}